VCEL Stock Overview
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States.
No risks detected for VCEL from our risk checks.
Vericel Corporation Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$34.24|
|52 Week High||US$39.90|
|52 Week Low||US$22.16|
|1 Month Change||-6.22%|
|3 Month Change||4.68%|
|1 Year Change||46.01%|
|3 Year Change||27.19%|
|5 Year Change||100.23%|
|Change since IPO||-96.94%|
Recent News & Updates
Vericel Corporation's (NASDAQ:VCEL) Shareholders Might Be Looking For ExitMay 05
Vericel Corporation: Stock Has Fallen, But Not Enough To Make This A BuyOct 10
Vericel Q2 2022 Earnings PreviewAug 02
Calculating The Fair Value Of Vericel Corporation (NASDAQ:VCEL)Apr 19
Vericel - A Disruptive Business With Years Of Growth RemainingApr 12
Vericel: In The Middle Of Difficulty Is An OpportunityDec 31
Vericel Corporation's (NASDAQ:VCEL) Intrinsic Value Is Potentially 19% Below Its Share PriceAug 09
Vericel: A Leader In Cell-Based TherapyMay 26
Vericel Q1 2021 Earnings PreviewMay 04
Statutory Profit Doesn't Reflect How Good Vericel's (NASDAQ:VCEL) Earnings AreMar 03
Is Vericel Corporation's (NASDAQ:VCEL) Recent Stock Performance Influenced By Its Fundamentals In Any Way?Feb 26
|VCEL||US Biotechs||US Market|
Return vs Industry: VCEL exceeded the US Biotechs industry which returned -4.6% over the past year.
Return vs Market: VCEL exceeded the US Market which returned 14.7% over the past year.
|VCEL Average Weekly Movement||7.5%|
|Biotechs Industry Average Movement||11.5%|
|Market Average Movement||6.1%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: VCEL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: VCEL's weekly volatility (8%) has been stable over the past year.
About the Company
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.
Vericel Corporation Fundamentals Summary
|VCEL fundamental statistics|
Is VCEL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|VCEL income statement (TTM)|
|Cost of Revenue||US$59.90m|
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
|Earnings per share (EPS)||-0.21|
|Net Profit Margin||-5.54%|
How did VCEL perform over the long term?See historical performance and comparison